Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
April W. Armstrong, Ahmed M. Soliman, Keith A. Betts, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 167-184
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
É. Sbidian, Anna Chaimani, Robin Guelimi, et al.
Cochrane library (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 85
Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis
Xuân‐Lan Lam Hoai, Thierry Simonart
Journal of Clinical Medicine (2023) Vol. 12, Iss. 16, pp. 5410-5410
Open Access | Times Cited: 13
Biological Agents for Psoriasis Management in HIV‐Positive Patients: A Literature Review
Miaoqi Qiu, Bo Feng, Chengyao Zhu, et al.
Dermatologic Therapy (2025) Vol. 2025, Iss. 1
Open Access
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months
Diamant Thaçi, Mamitaro Ohtsuki, Julia‐Tatjana Maul, et al.
Dermatology and Therapy (2025)
Open Access
Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
V. Gaudet, Irina Turchin, Charles Lynde, et al.
Dermatology and Therapy (2025)
Open Access
A Review of the Network Meta-Analysis and Psoriasis Management
Anastasiya Muntyanu
Canadian dermatology today. (2025)
Closed Access
Risankizumab, a therapeutic alternative for psoriasis in people living with HIV
Tomás Estevinho, Egídio Freitas, Tiago Torres
Journal of International Medical Research (2024) Vol. 52, Iss. 3
Open Access | Times Cited: 3
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
Edinson López, Raúl Cabrera, Cristóbal Lecaros
Anais Brasileiros de Dermatologia (2024) Vol. 99, Iss. 4, pp. 546-567
Open Access | Times Cited: 3
Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 5
Closed Access | Times Cited: 3
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: A Comprehensive Analysis from Clinical Trials
Kenneth B. Gordon, Andrew Blauvelt, H. Bachelez, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 9, pp. 2523-2538
Open Access | Times Cited: 3
Biological treatment for erythrodermic psoriasis
Sunil Dogra, Hitaishi Mehta
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1531-1543
Closed Access | Times Cited: 13
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Bruce Strober, Laura K. Ferris, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 1, pp. 82-90
Open Access | Times Cited: 7
Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities
Laura Mateu Arrom, L. Puig
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 4, pp. 363-379
Closed Access | Times Cited: 2
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
Richard B. Warren, Kerry Donnelly, Sandeep Kiri, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 11, pp. 3133-3147
Open Access | Times Cited: 2
Interleukin 17 and Its Involvement in Renal Cell Carcinoma
Michał Jarocki, Julia Karska, Szymon Kowalski, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 4973-4973
Open Access | Times Cited: 12
Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany
Nanna Nyholm, Henrik Schnack, Anne Danø, et al.
Current Medical Research and Opinion (2023) Vol. 39, Iss. 6, pp. 833-842
Open Access | Times Cited: 6
Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Dermatology and Therapy (2023) Vol. 14, Iss. 1, pp. 99-114
Open Access | Times Cited: 6
Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch
V. Gaudet, Belinda Yap, Shazia Hassan, et al.
Journal of Cutaneous Medicine and Surgery (2023) Vol. 27, Iss. 3, pp. 226-235
Closed Access | Times Cited: 5
Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series
Diego Orsini, Fabio Stefano Maramao, Luigi Gargiulo, et al.
International Journal of STD & AIDS (2023) Vol. 35, Iss. 1, pp. 67-70
Open Access | Times Cited: 5
Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
Hsien‐Yi Chiu, Yi‐Teng Hung, Yu‐Huei Huang
Therapeutic Advances in Chronic Disease (2023) Vol. 14
Open Access | Times Cited: 4
Risankizumab in the Management of Psoriasis in Solid Organ Transplant Recipients
Mariana Luz, Ana Maria Lé, T. Torres
Actas Dermo-Sifiliográficas (2024)
Open Access | Times Cited: 1
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score
Husein Husein‐ElAhmed, Sara Husein-ElAhmed
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 10, pp. 1148-1155
Closed Access | Times Cited: 1
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life Study
Elena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1378-1378
Open Access | Times Cited: 1
IL-17 and -23 Inhibitors for the Treatment of Psoriasis
Sonali Batta, Ramlah Khan, Marcus Zaayman, et al.
EMJ Allergy & Immunology (2023)
Open Access | Times Cited: 3
Interleukin 17 and Its Involvement in Renal Cell Carcinoma
Michał Jarocki, Julia Karska, Szymon Kowalski, et al.
(2022)
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top